Loading...
Loading...
Omnicare, Inc.
OCR today announced a
civil settlement with the United States Department of Justice relating
to a previously-disclosed investigation by the Drug Enforcement
Administration ("DEA") of alleged errors and deficiencies in dispensing
controlled substances by certain Omnicare pharmacies.
Pursuant to this civil settlement, Omnicare will pay the government $50
million. The settlement releases Omnicare's wholly-owned and joint
venture long-term care pharmacies from all civil penalty claims by the
DEA related to the subject matter of the investigation. The settlement
announced today has been fully reserved. The settlement contains no
allegation or finding that any controlled substances were unlawfully
diverted from the intended patient or that any patient was harmed.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in